PharmaNeuroBoost NV
This article was originally published in Start Up
Executive Summary
Belgian firm PharmaNeuroBoost NV creates NCEs out of existing therapeutics combined with the company’s proprietary boosting technology. The most advanced product in its pipeline, PNB01, is a combination of a low dose of pipamperone, a selective antagonist of the 5-HT2A and dopamine-4 receptors, with a fixed dose of the SSRI citalopram. It will soon embark on a Phase III pivotal trial comparing PNB01 with standard of care for treatment of major depressive disorder.